Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.

Essers PBM, van der Heijden M, Vossen D, de Roest RH, Leemans CR, Brakenhoff RH, van den Brekel MWM, Bartelink H, Verheij M, Vens C.

Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962. [Epub ahead of print]

PMID:
32167160
2.

Drug-target interaction prediction with tree-ensemble learning and output space reconstruction.

Pliakos K, Vens C.

BMC Bioinformatics. 2020 Feb 7;21(1):49. doi: 10.1186/s12859-020-3379-z.

3.

Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation.

van der Heijden M, Essers PBM, de Jong MC, de Roest RH, Sanduleanu S, Verhagen CVM, Hamming-Vrieze O, Hoebers F, Lambin P, Bartelink H, Leemans CR, Verheij M, Brakenhoff RH, van den Brekel MWM, Vens C.

Front Oncol. 2020 Jan 10;9:1470. doi: 10.3389/fonc.2019.01470. eCollection 2019.

4.

Predicting drug-target interactions with multi-label classification and label partitioning.

Pliakos K, Vens C, Tsoumakas G.

IEEE/ACM Trans Comput Biol Bioinform. 2019 Nov 4. doi: 10.1109/TCBB.2019.2951378. [Epub ahead of print]

PMID:
31689203
5.

Network inference with ensembles of bi-clustering trees.

Pliakos K, Vens C.

BMC Bioinformatics. 2019 Oct 28;20(1):525. doi: 10.1186/s12859-019-3104-y.

6.

Machine learning for discovering missing or wrong protein function annotations : A comparison using updated benchmark datasets.

Nakano FK, Lietaert M, Vens C.

BMC Bioinformatics. 2019 Sep 23;20(1):485. doi: 10.1186/s12859-019-3060-6. Review.

7.

Drug Sensitivity Prediction Models Reveal a Link between DNA Repair Defects and Poor Prognosis in HNSCC.

Essers PBM, van der Heijden M, Verhagen CVM, Ploeg EM, de Roest RH, Leemans CR, Brakenhoff RH, van den Brekel MWM, Bartelink H, Verheij M, Vens C.

Cancer Res. 2019 Nov 1;79(21):5597-5611. doi: 10.1158/0008-5472.CAN-18-3388. Epub 2019 Sep 12.

8.

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.

de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M.

BMC Cancer. 2019 Sep 10;19(1):901. doi: 10.1186/s12885-019-6121-3.

9.

Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models.

van Berlo D, Khmelinskii A, Gasparini A, Salguero FJ, Floot B, de Wit N, van de Ven M, Song JY, Coppes RP, Verheij M, Sonke JJ, Vens C.

Radiother Oncol. 2019 Sep;138:17-24. doi: 10.1016/j.radonc.2019.05.007. Epub 2019 May 27.

PMID:
31146069
10.

Acute Hypoxia Profile is a Stronger Prognostic Factor than Chronic Hypoxia in Advanced Stage Head and Neck Cancer Patients.

van der Heijden M, de Jong MC, Verhagen CVM, de Roest RH, Sanduleanu S, Hoebers F, Leemans CR, Brakenhoff RH, Vens C, Verheij M, van den Brekel MWM.

Cancers (Basel). 2019 Apr 25;11(4). pii: E583. doi: 10.3390/cancers11040583.

11.

Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy.

Vossen DM, Verhagen CVM, van der Heijden M, Essers PBM, Bartelink H, Verheij M, Wessels LFA, van den Brekel MWM, Vens C.

Cancers (Basel). 2019 Mar 29;11(4). pii: E445. doi: 10.3390/cancers11040445.

12.

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association.

Vossen DM, Verhagen CVM, Grénman R, Kluin RJC, Verheij M, van den Brekel MWM, Wessels LFA, Vens C.

PLoS One. 2018 Nov 8;13(11):e0206632. doi: 10.1371/journal.pone.0206632. eCollection 2018.

13.

DNA Repair Molecular Beacon assay: a platform for real-time functional analysis of cellular DNA repair capacity.

Li J, Svilar D, McClellan S, Kim JH, Ahn EE, Vens C, Wilson DM 3rd, Sobol RW.

Oncotarget. 2018 Aug 3;9(60):31719-31743. doi: 10.18632/oncotarget.25859. eCollection 2018 Aug 3.

14.

Mining features for biomedical data using clustering tree ensembles.

Pliakos K, Vens C.

J Biomed Inform. 2018 Sep;85:40-48. doi: 10.1016/j.jbi.2018.07.012. Epub 2018 Jul 29.

15.

Comparative genomic analysis of oral versus laryngeal and pharyngeal cancer.

Vossen DM, Verhagen CVM, Verheij M, Wessels LFA, Vens C, van den Brekel MWM.

Oral Oncol. 2018 Jun;81:35-44. doi: 10.1016/j.oraloncology.2018.04.006. Epub 2018 Apr 13.

PMID:
29884412
16.

Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.

Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C.

Oncotarget. 2018 Apr 6;9(26):18198-18213. doi: 10.18632/oncotarget.24797. eCollection 2018 Apr 6.

17.

A machine learning based framework to identify and classify long terminal repeat retrotransposons.

Schietgat L, Vens C, Cerri R, Fischer CN, Costa E, Ramon J, Carareto CMA, Blockeel H.

PLoS Comput Biol. 2018 Apr 23;14(4):e1006097. doi: 10.1371/journal.pcbi.1006097. eCollection 2018 Apr.

18.

Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials.

de Haan R, Pluim D, van Triest B, van den Heuvel M, Peulen H, van Berlo D, George J, Verheij M, Schellens JHM, Vens C.

Radiother Oncol. 2018 Mar;126(3):443-449. doi: 10.1016/j.radonc.2017.10.017. Epub 2017 Nov 14.

19.

Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity.

Dohmen AJC, Qiao X, Duursma A, Wijdeven RH, Lieftink C, Hageman F, Morris B, Halonen P, Vens C, van den Brekel MWM, Ovaa H, Neefjes J, Zuur CL.

Oncotarget. 2017 May 19;8(43):73925-73937. doi: 10.18632/oncotarget.18034. eCollection 2017 Sep 26.

20.

Predicting human olfactory perception from chemical features of odor molecules.

Keller A, Gerkin RC, Guan Y, Dhurandhar A, Turu G, Szalai B, Mainland JD, Ihara Y, Yu CW, Wolfinger R, Vens C, Schietgat L, De Grave K, Norel R; DREAM Olfaction Prediction Consortium, Stolovitzky G, Cecchi GA, Vosshall LB, Meyer P.

Science. 2017 Feb 24;355(6327):820-826. doi: 10.1126/science.aal2014. Epub 2017 Feb 20.

21.

Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland.

Ghobadi G, de Jong J, Hollmann BG, van Triest B, van der Poel HG, Vens C, van der Heide UA.

Radiother Oncol. 2016 Apr;119(1):97-103. doi: 10.1016/j.radonc.2016.02.015. Epub 2016 Feb 16.

22.

A benchmark for evaluation of algorithms for identification of cellular correlates of clinical outcomes.

Aghaeepour N, Chattopadhyay P, Chikina M, Dhaene T, Van Gassen S, Kursa M, Lambrecht BN, Malek M, McLachlan GJ, Qian Y, Qiu P, Saeys Y, Stanton R, Tong D, Vens C, Walkowiak S, Wang K, Finak G, Gottardo R, Mosmann T, Nolan GP, Scheuermann RH, Brinkman RR.

Cytometry A. 2016 Jan;89(1):16-21. doi: 10.1002/cyto.a.22732. Epub 2015 Oct 8.

23.

FloReMi: Flow density survival regression using minimal feature redundancy.

Van Gassen S, Vens C, Dhaene T, Lambrecht BN, Saeys Y.

Cytometry A. 2016 Jan;89(1):22-9. doi: 10.1002/cyto.a.22734. Epub 2015 Aug 4.

24.

Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.

Verhagen CV, de Haan R, Hageman F, Oostendorp TP, Carli AL, O'Connor MJ, Jonkers J, Verheij M, van den Brekel MW, Vens C.

Radiother Oncol. 2015 Sep;116(3):358-65. doi: 10.1016/j.radonc.2015.03.028. Epub 2015 May 13.

PMID:
25981132
25.

New challenge of developing combined radio-drug therapy.

Maingon P, Govaerts AS, Rivera S, Vens C, Shash E, Grégoire V.

Chin Clin Oncol. 2014 Jun;3(2):18. doi: 10.3978/j.issn.2304-3865.2014.05.14.

26.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.

Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.

27.

Learning HMMs for nucleotide sequences from amino acid alignments.

Fischer CN, Carareto CM, dos Santos RA, Cerri R, Costa E, Schietgat L, Vens C.

Bioinformatics. 2015 Jun 1;31(11):1836-8. doi: 10.1093/bioinformatics/btv054. Epub 2015 Jan 31.

PMID:
25638811
28.

HSP90 regulates DNA repair via the interaction between XRCC1 and DNA polymerase β.

Fang Q, Inanc B, Schamus S, Wang XH, Wei L, Brown AR, Svilar D, Sugrue KF, Goellner EM, Zeng X, Yates NA, Lan L, Vens C, Sobol RW.

Nat Commun. 2014 Nov 26;5:5513. doi: 10.1038/ncomms6513.

29.

Tight regulation of ubiquitin-mediated DNA damage response by USP3 preserves the functional integrity of hematopoietic stem cells.

Lancini C, van den Berk PC, Vissers JH, Gargiulo G, Song JY, Hulsman D, Serresi M, Tanger E, Blom M, Vens C, van Lohuizen M, Jacobs H, Citterio E.

J Exp Med. 2014 Aug 25;211(9):1759-77. doi: 10.1084/jem.20131436. Epub 2014 Aug 11.

30.

NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.

Zerp SF, Vens C, Floot B, Verheij M, van Triest B.

Radiother Oncol. 2014 Feb;110(2):348-54. doi: 10.1016/j.radonc.2013.10.039. Epub 2014 Jan 8.

PMID:
24412016
31.

Top-down clustering for protein subfamily identification.

Costa EP, Vens C, Blockeel H.

Evol Bioinform Online. 2013 May 6;9:185-202. doi: 10.4137/EBO.S11609. Print 2013.

32.
33.

Strategies to improve radiotherapy with targeted drugs.

Begg AC, Stewart FA, Vens C.

Nat Rev Cancer. 2011 Apr;11(4):239-53. doi: 10.1038/nrc3007. Review.

PMID:
21430696
34.

Identifying discriminative classification-based motifs in biological sequences.

Vens C, Rosso MN, Danchin EG.

Bioinformatics. 2011 May 1;27(9):1231-8. doi: 10.1093/bioinformatics/btr110. Epub 2011 Mar 3.

PMID:
21372086
35.

Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}.

Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, Begg AC, Vens C.

Cancer Res. 2010 Nov 1;70(21):8706-14. doi: 10.1158/0008-5472.CAN-09-3901. Epub 2010 Oct 26.

36.

Targeting base excision repair as a sensitization strategy in radiotherapy.

Vens C, Begg AC.

Semin Radiat Oncol. 2010 Oct;20(4):241-9. doi: 10.1016/j.semradonc.2010.05.005. Review.

PMID:
20832016
37.

Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective.

Verheij M, Vens C, van Triest B.

Drug Resist Updat. 2010 Feb-Apr;13(1-2):29-43. doi: 10.1016/j.drup.2010.01.002. Epub 2010 Feb 18. Review.

PMID:
20167530
38.

Predicting gene function using hierarchical multi-label decision tree ensembles.

Schietgat L, Vens C, Struyf J, Blockeel H, Kocev D, Dzeroski S.

BMC Bioinformatics. 2010 Jan 2;11:2. doi: 10.1186/1471-2105-11-2.

39.

Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta.

Neijenhuis S, Verwijs-Janssen M, Kasten-Pisula U, Rumping G, Borgmann K, Dikomey E, Begg AC, Vens C.

DNA Repair (Amst). 2009 Mar 1;8(3):336-46. doi: 10.1016/j.dnarep.2008.11.008. Epub 2008 Dec 27.

PMID:
19059500
40.

Cell cycle phase dependent role of DNA polymerase beta in DNA repair and survival after ionizing radiation.

Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C.

Radiother Oncol. 2008 Mar;86(3):391-8. doi: 10.1016/j.radonc.2008.01.002. Epub 2008 Jan 30.

PMID:
18237797
41.

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

Zimmermann C, van de Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH.

Drug Metab Dispos. 2008 Apr;36(4):631-40. doi: 10.1124/dmd.107.019620. Epub 2008 Jan 7.

PMID:
18180270
42.

Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells.

Vermeulen C, Bertocci B, Begg AC, Vens C.

Radiat Res. 2007 Dec;168(6):683-8.

PMID:
18088185
43.
44.

Role for DNA polymerase beta in response to ionizing radiation.

Vermeulen C, Verwijs-Janssen M, Cramers P, Begg AC, Vens C.

DNA Repair (Amst). 2007 Feb 4;6(2):202-12. Epub 2006 Nov 28.

PMID:
17126614
45.

Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status.

Sprong D, Janssen HL, Vens C, Begg AC.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):562-72. Epub 2005 Dec 15.

PMID:
16343804
46.
47.

The role of DNA polymerase beta in determining sensitivity to ionizing radiation in human tumor cells.

Vens C, Dahmen-Mooren E, Verwijs-Janssen M, Blyweert W, Graversen L, Bartelink H, Begg AC.

Nucleic Acids Res. 2002 Jul 1;30(13):2995-3004.

48.

Rapid fluorescence ratio assay for detecting changes in radiosensitivity.

Hofland I, Ramakers B, Begg AC, Vens C.

Radiat Res. 2002 Jun;157(6):734-9.

PMID:
12005553
49.

Genetic manipulation of radiosensitivity.

Begg AC, Vens C.

Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):367-71. No abstract available.

PMID:
11173129
50.

T cell activation responses are differentially regulated during clinorotation and in spaceflight.

Hashemi BB, Penkala JE, Vens C, Huls H, Cubbage M, Sams CF.

FASEB J. 1999 Nov;13(14):2071-82.

PMID:
10544190

Supplemental Content

Support Center